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Abstract
Introduction: Previous studies have documented a high frequency of endotoxemia associated with
cardiopulmonary bypass (CPB). Endotoxemia may be responsible for some of the complications associated with
cardiac surgery. The purpose of the study was to examine the prevalence of endotoxemia during cardiopulmonary
bypass supported aortocoronary bypass grafting surgery (ACB) using a new assay, the Endotoxin Activity Assay
(EAA), and explore the association between endotoxemia and post-operative infection.
Methods: The study was a single center prospective observational study measuring EAA during the perioperative
period for elective ACB. Blood samples were drawn at induction of anesthesia (T1), immediately prior to release of
the aortic cross-clamp (T2), and on the first post-operative morning (T3). The primary outcome was the prevalence
of endotoxemia. Secondary outcomes assessed included infection rates, intensive care unit (ICU) and hospital
length of stay. An EAA of < 0.40 units was interpreted as “low”, 0.41 to 0.59 units as “intermediate”, and ≥0.60 units
as “high”.
Results: A total of 57 patients were enrolled and 54 patients were analyzable. The mean EAA at T1 was 0.38 +/-
0.14, at T2 0.39 +/- 0.18, and at T3 0.33 +/- 0.18. At T2 only 13.5% (7/52) of patients had an EAA in the high range.
There was a positive correlation between EAA and duration of surgery (P = 0.02). In patients with EAA ≥0.40 at T2,
26.1% (6/23) of patients developed post-operative infections compared to 3.5% (1/29) of those that had a normal
EAA (P = 0.0354). Maximum EAA over the first 24 hours was also strongly correlated with risk of post-operative
infection (P = 0.0276).
Conclusions: High levels of endotoxin occur less frequently during ACB than previously documented. However,
endotoxemia is associated with a significantly increased risk of the development of post-operative infection.
Measuring endotoxin levels during ACB may provide a mechanism to identify and target a high risk patient
population.
Introduction
Since the beginnings of cardiopulmonary bypass (CPB)
supported cardiac surgery in the 1950’s, clinicians and
surgeons have faced the challenge of balancing the
desire to achieve optimal surgical results, while minimiz-
ing the consequences of exposure to cardiac bypass
[1,2]. The inflammatory response to CPB has been
implicated in many of the post-operative clinical
problems that often occur in these patients including
coagulopathy, respiratory failure, post-operative shock
states, and multiple organ failure [3]. The pathophysiol-
ogy of this inflammatory response is thought to involve
a cascade of complement activation, activation of intrin-
sic and extrinsic coagulation systems, as well as activa-
tion of cellular components of inflammation and
alterations in immune function [3]. Numerous cytokines
and inflammatory mediators have been found to rise in
patients exposed to CPB including IL-1b,I L - 6 ,I L - 8 ,
TNF-a [4-6].
Endotoxin, or lipopolysaccharide (LPS), is a key com-
ponent of the cell membrane of gram negative bacteria.
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medium, provided the original work is properly cited.Endotoxin is one of the most potent known activators of
innate immunity and the inflammatory response in
humans [7]. It was first identified in the serum of
patients undergoing CPB over 20 years ago and pro-
posed as a potential mediator of multiple organ failure
and prolonged recovery after cardiac surgery [8]. Endo-
toxin is hypothesized to enter the systemic circulation
during CPB by translocation of gut commensal microbes
or LPS fragments across the intestinal mucosal barrier
during the period of relative hypotension and hypoper-
fusion associated with extracorporeal support [9]. The
prevalence of endotoxemia in patients on cardiopulmon-
ary bypass has been estimated at up to 100% of ACB
patients, although estimates are highly variable [8,9].
Endotoxin’st r u ep a t h o l o g i cr o l ed u r i n ga n da f t e rC P B ,
however, has been called into question as it has been
difficult to correlate the degree of endotoxemia with
adverse clinical outcomes. Several therapeutic strategies
directed at minimizing or treating endotoxemia as a
consequence of CPB including selective gut decontami-
nation, pulsatile flow extracorporeal pumps, and LPS
receptor inhibitors have been tried in patients without
success [10-12]. In addition, the estimated prevalence of
endotoxemia during cardiopulmonary bypass may be
unreliable due to the challenges of assaying endotoxin
in vivo using the traditional Limulus Amoebocyte Lysate
(LAL) assay [13].
To clarify the role of endotoxemia, we investigated the
prevalence of endotoxemia related to CPB in a cohort of
patients undergoing elective cardiac surgery using the
EAA for the measurement of endotoxin in blood. We
further investigated the association between endotoxe-
mia and the development of adverse clinical events
including length of stay and development of post-opera-
tive infections.
Materials and methods
Study design
The study protocol was approved by the Research Ethic
Board of St. Michael’s Hospital. All subjects provided
written informed consent. All patients were scheduled
to undergo elective on-pump cardiac bypass surgery at
St. Michael’s Hospital in Toronto, Ontario, Canada.
Patients were excluded if they had a history of recent
myocardial infarction (less than one week), required
redo surgery, emergent surgery or a surgical procedure
in addition to ACB (for example, valve replacement).
The study also excluded patients with other co-morbid-
ities that involve significant active inflammation such as
Crohn’s disease, ulcerative colitis, HIV, a bone marrow
disorder, active cancer, or significant renal insufficiency
(creatinine >133 umol/L). Patients were enrolled
between August 2005 and December 2007.
Intra-operative management
All patients remained on their pre-operative medications
as directed until the surgical date. Patients were
anesthetized using a narcotic (sufentanil 1 to 2 μg/kg or
fentanyl 10 to 20 μg/kg), a benzodiazepine (midazolam
0.1 to 0.15 mg/kg), isoflurane 0.2 to 1.5% and/or propo-
fol 50 to 100 μg/kg/min, with muscle relaxation pro-
vided from rocuronium 0.6 to 1.0 mg/kg or
pancuronium 0.1 mg/kg. Heparin was given to maintain
an activated clotting time (ACT) >420 seconds during
CPB. Bypass management included non-pulsatile pump
flow of 2.4 L/minute/m
2 of BSA, mean arterial pressure
55 to 85 mmHg, temperature 33 to 35°C, and blood
sugar 4 to 10 mmol/L. Myocardial protection was
achieved with cold blood crystalloid cardioplegia, and a
“hot-shot” (250 to 500 mL) was delivered just prior to
the removal of the aortic cross-clamp. After separation
from CPB, heparin was reversed with protamine
(approximately 10 mg/1,000 units of heparin). Post-
operatively, patients were managed in a specialized car-
diovascular intensive care unit with standardized
protocols for early extubation (two to four hours) and
blood glucose control (target 5.1 to 8.0 mmol/L).
Data collection
Data were collected by a dedicated clinical research nurse
a n di n c l u d e dp a t i e n td e m o g r aphics, laboratory values
including hematology, coagulation parameters, biochem-
istry, and liver and renal functions. Intra-operative data
collected included duration of surgery and duration of
bypass time up until the removal of the aortic cross
clamp. We defined three time points for EAA collection:
at the induction of general anesthesia (T1), at the time of
removal of the aortic cross clamp after CPB (T2), and on
the first post operative morning (T3). In addition, culture
results were tracked and infection was established based
on a clinical diagnosis. Length of intensive care unit stay
and hospital stay were also tracked.
Endotoxin activity assay
Endotoxin in whole blood was measured using the che-
miluminescent endotoxin activity assay (EAA), as recom-
mended by the manufacturer (Spectral Diagnostics,
Toronto, ON, Canada). The methodology is described in
detail elsewhere [14]. Briefly, samples of 50 μlo fw h o l e
blood and appropriate controls were incubated in dupli-
cate with saturating concentrations of an anti-lipid A
IgM antibody, and then stimulated with opsonized zymo-
san. The resulting respiratory burst activity was detected
as light release from the lumiphor, luminol, using a che-
miluminometer (E.G. & G. Berthold Autolumat LB953,
Wildbad, Germany). The LPS/anti-LPS complex primes
the patient’s neutrophils for an augmented response to
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body) and maximally stimulated (2,000 pg/ml LPS)
responses in the same blood sample, the endotoxin activ-
ity of the test specimen is calculated by integrating che-
miluminescence over time. Thus, the result is
independent of white cell count or white cell responsive-
ness. Levels are expressed as endotoxin activity units, and
represent the mean of duplicate determinations from the
same sample. A level of less than 0.40 is defined as low, a
level of 0.41 to 0.59 is defined as intermediately elevated,
and a level of >0.60 is defined as highly elevated as per
the recommendations of the manufacturer.
Statistical analysis
Means, standard deviations and proportions were used
to describe patients’ characteristics. Group differences
were examined using the chi-square or Fisher’se x a c t
test in binary variables, and the t-test or Wilcoxon rank
sum test in continuous variables. We defined elevated
EAA levels using three cut-off values: ≥0.40, ≥0.50, and
≥0.60. To account for correlations among repeated mea-
sures for each patient and for a few missing EAA values,
change in EAA levels over time was evaluated using
mixed models. Factors associated with the prevalence of
elevated EAA pre-operatively (T1), at the time of the
removal of the aortic cross-clamp (T2), and at 24 hours
post-operatively (T3), were determined using generalized
estimating equations. An unstructured covariance matrix
was assumed in both models. All tests were two-sided
and statistical significance was assumed for a P-value of
≤ 0.05. Analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
Fifty-seven patients were enrolled. One patient was
excluded from the analysis because of lack of EAA data
and 2 patients were excluded because of withdrawal of
consent resulting in a sample size of 54 patients. Of these
54 participants, the mean age was 57.5 +/- 8.1, most were
males (85.2%), 35.2% were current smokers, 46.3% had
confirmed diabetes and 44.4% were obese (BMI ≥30)
(Table 1). There were no statistically significant differ-
ences in patient characteristics between diabetic and
non-diabetic patients. There was one death in the cohort
due to cardiac arrest after a massive aspiration event.
Endotoxin levels
The distribution of endotoxin levels at the three mea-
sured time points is represented in Figure 1. The mean
EAA level at T1 was 0.38 +/- 0.14, at T2 was 0.39 +/-
0.19, and at T3 was 0.33 +/- 0.18. The prevalence of ele-
vated EAA was at T1, T2, and T3 respectively: 48.1%,
44.2%, and 36.5% of patients had an EAA ≥0.40; 21.2%,
30.8%, and 15.4% had an EAA ≥0.50; and 5.8%, 13.5%,
and 7.7% had an EAA ≥0.60. There were no significant
changes in prevalence of elevated EAA over time. Preva-
lence of EAA ≥0.40 across all time points was similar
for smokers and non-smokers (odds ratio 0.81 (CI: 0.35
to 1.88), and was not associated with age (odd ratio 1.01
(CI: 0.96 to 1.07)).
Duration of surgery and cardiac bypass time
The median duration of surgery was 190 minutes (inter-
quartile range (IQR) = 45 minutes). The median dura-
tion of cross clamp time was 56 minutes (IQR = 25
minutes). There was a significant correlation between
EAA levels at T2 and the duration of surgery (Pearson
correlation coefficient = 0.32, P = 0.02).
Length of stay
The median length of hospital stay was seven days (IQR:
six days), and 23 (43.4%) patients had a length of stay
Table 1 Patient characteristics (n = 54)
Characteristics
% Males 85.2
Mean age (SD) 57.5 (8.1)
% Current smoker 35.2
% Diabetic 46.3
Mean (SD) BMI 30.34 (5.41)
% 18.50 to 24.99 14.8
% 25.00 to 29.99 40.7
% ≥30.00 44.5
Mean creatinine ( umol/L) (SD) 91.7 (22.4)
% Hypertension 77.8
% Hyperlipidemia 74.1
Median (IQR) duration of surgery (minutes) 190 (45)
Median (IQR) duration of cross-clamping (minutes) 56 (25)
BMI, body mass index; IQR, inter-quartile range; SD, standard deviation.
Figure 1 Endotoxin Activity Assay measurement. T1, induction
of anesthesia; T2, at the time of removal of aortic cross clamp after
CPB,; and T3, on the first postoperative morning. High EAA levels
were rare at any time point.
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length of stay of 61 days associated with multiple com-
plications. There were no statistically significant differ-
ences in length of stay for patients with EAA ≥0.40
versus patients with EAA < 0.40 at any point in time.
Infections
All patients underwent elective surgical screening proce-
dures pre-operatively and none had clinical evidence of
infection prior to surgery. A total of eight patients (14.8%)
in the cohort developed postoperative infections. There
were three cases of urosepsis, two cases of sternal wound
infection or mediastinitis, three cases of cellulitis at the
site of vein graft harvesting, and one case of pneumonia.
One patient developed both urosepsis and wound celluli-
tis. EAA results for patients who developed infections ver-
sus those who did not are shown in Figure 2. In patients
with EAA ≥0.40 at T2, 26.1% (6/23) of patients developed
post-operative infections compared to 3.5% (1/29) of those
that had a normal EAA (P = 0.0354). There was a non-sig-
nificant trend for EAA levels at baseline to also be higher
in patients that developed postoperative infections than in
those that did not (mean (SD) = 0.46 (0.14) versus 0.36
(0.13), respectively). Differences were only statistically sig-
nificant at T2 (median IQR) = 0.58 (0.41) and 0.36 (0.22),
P = 0.0236. Similarly, the maximum EAA level across all
the three time points was strongly associated with risk of
subsequent infection (median IQR) = 0.62 (0.23) versus
0.45 (0.24) in the infection and no infection group, respec-
tively (P = 0.0276).
Discussion
In this study, we validate previous reports that endotoxe-
mia occurs in patients exposed to CPB utilizing a novel
independent method for measuring endotoxin in vivo.
While our observed prevalence of endotoxemia at the
end of CPB at 44.2% is similar to some reports, it is lower
than many studies that have reported the frequency of
endotoxemia related to CPB at as much as 100% [15,16].
Further, the incidence of patients having levels of endo-
toxin similar to those that might be observed in patients
with severe sepsis (EAA >0.60), was quite low in our
study, with only 7.7% of patients having this high level on
this first post-operative morning [17]. There are several
possible explanations for these observations. Prior studies
have utilized the LAL assay. The LAL assay, however, has
not proven to be dependable for quantitation of endo-
toxin in human blood or plasma due to interference from
metals, amino acids, hormones, alkaloids, plasma pro-
teins, electrolytes and antibiotics [18]. Dilution enhance-
ment is a common problem with the LAL assay and this
effect may be compounded in a cardiac bypass patient
population due to changes in plasma composition during
the course of, and following, the bypass procedure due to
the use of cardioplegia solutions, crystalloids and hemo-
dilution. In addition, we selected for study a relatively
low risk cohort of patients going for cardiac surgery. All
underwent elective procedures, those with advanced
renal disease were excluded, as were those having com-
plex valve operations or redo operations. Thus, exposure
to prolonged periods of CPB was limited. Further, since
the time of publication of previous reports, there have
been substantial improvements in anesthetic techniques,
perfusion practices, and in cardiopulmonary bypass cir-
cuits themselves [19]. These improvements likely have
decreased the incidence of endotoxemia during CPB
through a variety of mechanisms including decreased
activation of coagulation factors and complement,
improved tissue oxygen delivery and, therefore, decreased
ischemia-reperfusion injury to the bowel, and shortened
exposure time to the CPB circuit. Finally, the timing and
frequency of sampling may influence our observations
compared to previous reports such as the study by Boelke
et al., which observed that endotoxin levels peaked at
reperfusion but remained quite elevated six hours post-
operatively before decreasing to an only slightly elevated
level on Day 1 [16].
Interestingly, we observed that a substantial number of
patients presenting for elective cardiac surgery had small
elevations in endotoxin levels before surgery. While
active smoking has been associated with endotoxemia,
we did not find a similar correlation in our cohort with
subjective smoking status onh i s t o r y .H o w e v e r ,w ed i d
not adjudicate the time of the patient’s last cigarette
[20]. Others have found elevations in endotoxin levels
associated with chronic heart disease including severe
heart failure [21,22]. It has been hypothesized that trans-
location of endotoxin from the gut in these cases
Figure 2 Box plots for EAA levels in patients that developed
post-operative infection versus those that did not. Before (T1, P
= 0.0796), during (T2, P = 0.0236) and after CPB (T3, P = 0.8203).
Patients who went on to develop post-operative infection had
significantly higher EAA levels at T2.
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tion of the inflammatory cascade. We did not specifi-
cally measure left ventricular ejection fraction prior to
surgery in our study. Further support to the validity of
the observed levels of endotoxin preoperatively is the
known presence of endogenous anti-endotoxin antibo-
dies in patients going for cardiac surgery [23].
Infection is a common complication after cardiac sur-
gery. The finding of a substantially increased risk of
post-operative infections in patients who have endotoxe-
mia after CPB is novel. Given the elective nature of the
surgical patients and their extensive pre-operative
screening, it is unlikely that they had occult infections
prior to surgery or developed them intraoperatively.
Rather, we suggest that perioperative endotoxemia
results from translocation of endotoxin from gut com-
mensal bacterial flora during CPB. Thus, this period of
endotoxemia represents the first “hit” in a two “hit”
model of risk. Faist et al. first used this “two hit”
hypothesis to describe the increased risk of development
of sepsis in patients after polytrauma [24]. Similar mod-
els have been described in other critical illnesses includ-
ing burns [25]. Volk et al. have described this
phenomenon as “immunoparalysis”, whereby patients
subjected to a first “hit” down-regulate HLA-DR4+
monocytes in response to an acute rise in inflammatory
mediators including IL-8 and TNF-a [26]. These
patients have been found to have an increased risk of
postoperative infections. It has been hypothesized that
this phenomenon may be linked to translocation of
endotoxin [27]. It has been further suggested that
immune monitoring in the postoperative period may be
useful in identifying patients at risk [27]. Faist et al.
have also described a pilot-clinical trial of GM-CSF to
counter immunoparalysis [28]. Conversely, the finding
of antibodies to endotoxin in patient’s blood prior to
gynecologic surgery has been found to reduce the risk
of post operative infections [29].
Attempts to therapeutically target endotoxin in
patients going for cardiac surgery have largely been dis-
appointing. Strategies have included antagonists to the
endotoxin Toll-like receptor 4 (TLR4), extracorporeal
endotoxin removal systems, performance “off pump”
cardiac surgery to eliminate CPB exposure, engineered
anti-endotoxin monoclonal antibodies as well as other
methods [10,30,31]. We hypothesize that these failures
may in part be explained by our findings of a relatively
lower prevalence of high amounts of endotoxin in CPB
patients after surgery coupled with the failure of these
studies to measure endotoxin during or after CPB and
specifically target the sub-population of patients who
develop endotoxemia.
Our study has a number of important limitations.
First, we studied a relatively low risk patient population
and thus had a small number of patients for the deter-
mination of “hard” clinical outcomes, such as infection
or mortality. Validation of these finding in multiple cen-
ters in larger numbers of patients is also warranted. In
addition, it has been suggested that hemodilution of
endotoxin by the administration of endotoxin free crys-
talloid solutions during CPB may lead to an underesti-
mation of “true” circulating endotoxin levels.
Nevertheless, previous studies similarly did not correct
for hemodilution and thus we did not to do so for com-
parative purposes. We are not aware of any validated
correction factor for hemodilution for endotoxin levels
with any assay as endotoxin exists in many forms and
compartments in vivo and the impact of hemodilution
on each of these is unknown. In addition, we did not
measure other inflammatory markers and immune mar-
kers in our study.
Conclusions
This study confirms, with us using an independent
method, that endotoxemia occurs in some patients hav-
ing cardiac surgery, although rarely at high levels.
Importantly, endotoxemia at the conclusion of CPB is
associated with a significant risk of the development of
postoperative infections. Further research is necessary to
assess whether a targeted strategy of rapid measurement
of endotoxin levels coupled with a directed anti-endo-
toxin therapeutic strategy could improve patient
outcomes.
Key messages
￿ The prevalence of high levels of endotoxemia (as
measured by the Endotoxin Activity Assay) in
patients undergoing elective cardiopulmonary bypass
supported aortocoronary bypass grafting surgery is
uncommon compared to previous reports
￿ Endotoxemia correlates with the duration of
surgery
￿ Patients who do have cardiopulmonary bypass
associated endotoxemia are at a significantly
increased eight-fold risk of developing post-operative
infections
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